These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Daan NM; Louwers YV; Koster MP; Eijkemans MJ; de Rijke YB; Lentjes EW; Fauser BC; Laven JS Fertil Steril; 2014 Nov; 102(5):1444-1451.e3. PubMed ID: 25239303 [TBL] [Abstract][Full Text] [Related]
5. Is cardiovascular risk in women with PCOS a real risk? Current insights. Papadakis G; Kandaraki E; Papalou O; Vryonidou A; Diamanti-Kandarakis E Minerva Endocrinol; 2017 Dec; 42(4):340-355. PubMed ID: 28146139 [TBL] [Abstract][Full Text] [Related]
6. Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary syndrome: A case-control study. Ng NYH; Jiang G; Cheung LP; Zhang Y; Tam CHT; Luk AOY; Quan J; Lau ESH; Yau TTL; Chan MHM; Ho CS; Lim CKP; Ozaki R; Huang J; Liu KH; Tam WH; Sahota DS; Chu WCW; Goggins W; Woo J; Li TC; Chow CC; Chan JCN; Ma RCW PLoS Med; 2019 Oct; 16(10):e1002953. PubMed ID: 31652273 [TBL] [Abstract][Full Text] [Related]
7. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Jeanes YM; Reeves S Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828 [TBL] [Abstract][Full Text] [Related]
8. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome. Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233 [TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes and the polycystic ovary syndrome. Pelusi B; Gambineri A; Pasquali R Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409 [TBL] [Abstract][Full Text] [Related]
10. [Chronic inflammation and metabolic syndrome in comparison with other signs belonging to the image of polycystic ovary syndrome]. Marciniak A; Nawrocka-Rutkowska J; Wiśniewska B; Brodowska A; Starczewski A Pol Merkur Lekarski; 2013 Apr; 34(202):228-31. PubMed ID: 23745331 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort. Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903 [TBL] [Abstract][Full Text] [Related]
12. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205 [TBL] [Abstract][Full Text] [Related]
13. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199 [TBL] [Abstract][Full Text] [Related]